GO
Loading...

Exelixis Inc

More

  • Cramer: Retail Investors Returning to Market? Monday, 16 Nov 2009 | 3:34 PM ET

    Plus, get calls on tech, pharma and more.

  • No Product Revenues, Plenty of Risk: Buy Exelixis? Friday, 6 Nov 2009 | 7:57 PM ET

    Since when is profitability a prerequisite for speculation? Find out why Cramer thinks you should get in on this stock.

  • Lightning Round OT: Arch Coal, Exelixis and More Wednesday, 3 Jun 2009 | 7:57 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • Biotech Breakthrough In Cancer Thursday, 28 May 2009 | 6:02 PM ET

    The fight against cancer sparked a new partnership – and both the medical community and financial community are celebrating.

  • Pharma's Feeding Frenzy Thursday, 28 May 2009 | 12:58 PM ET

    Consumers may be saving more and spending less, but big pharma is on a shopping spree. And I'm not talking about the really big deals including Roche buying Genentech, Pfizer buying Wyeth and Merck buying Schering-Plough. I'm talking about the two deals that have been done in less than a week between major drug companies and baby biotechs specializing in oncology.

  • Stocks End Down Week With a Flop Friday, 15 May 2009 | 4:49 PM ET

    Stocks flopped Friday, capping a dismal week, as bank stocks pulled back after recent gains.

  • Stocks Struggle Despite Shot of Confidence Friday, 15 May 2009 | 11:23 AM ET

    Stocks opened flat Friday as investors were encouraged by a pair of better-than-expected manufacturing readings but dismal economic data out of Europe and weak U.S. retail reports capped gains.

  • Expect Big Pharma Moves Friday Thursday, 14 May 2009 | 5:58 PM ET

    Investors are closely watching the latest ASCO data released Thursday 6pm ET. Results seem likely to move the market.

  • Intel Points To Higher Open Tuesday, 12 May 2009 | 5:48 PM ET

    Comments made by Intel CEO Paul Otellini after hours could be bullish for stocks.

  • NEJM Gets At Heart Of Pfizer's/Pharma's Problems Wednesday, 18 Mar 2009 | 5:15 PM ET

    Scientific and medical journals like to keep their distance from the business side of things. That's why I think it's worth noting that a "Perspective" piece--think of it as kind of a newspaper Op-Ed--in "The New England Journal of Medicine" starts by mentioning Pfizer's stock price and its recent proposed acquisition of Wyeth.

  • Biogen Idec: First Of A Biotech Buying Binge? Monday, 15 Oct 2007 | 12:52 PM ET

    For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.

  • Pfizer's Inside R&D Move: Are Investors Buying It? Thursday, 4 Oct 2007 | 1:25 PM ET

    Close on the heels of announcing the hiring of a Chief Talent Officer, Pfizer this morning named a new head of Global Research and Development to replace John LaMattina who had earlier said he'd be leaving the drug company. It was on LaMattina's watch that Pfizer's next potential breakout blockbuster drug, torcetrapib for cholesterol, failed in a late-stage clinical trial.